I believe some really good science, that people can readily understand, is coming CYDY's way. Other Covid19 trials have recently shown mortality around 30% or above in the SOC arm of their trials, and with CYDY implying an approximate 22% mortality rate for their SOC arm & treatment arm combined, things look very positive for Vyrologix to me. My expectation is that there will be a very helpful reduction in mortality shown in this CYDY trial's primary endpoint.

Next I'd like to mention that the open label extension, the continuing eIND's, the Philippines allocation, and the Medicare billing code give me comfort while we await results from CD12.

Of course I'd like to have heard results already, however I remind myself that good results will validate a drug that will disrupt the field of medicine. I try to maintain patience for all involved that are making sure they have a strong data set, so that they can best present a beautiful new tool to the world. I do also believe that at some point before we hear results, I expect the CEO will be working a lot of deals for production and distribution.

I expect a maximum of 28 day data from this trial, since as far as I know, observations past 28 days were never added to the official endpoints. For simplicity's sake and also for expediting timelines to approval, I believe they made a choice to stick to the max 28 day endpoints.

The current silence I think won't last much longer. All IMHO.